Advances in the use of exosomes for the treatment of ALI/ARDS

Chang Liu; Kun Xiao; Lixin Xie

doi:10.3389/fimmu.2022.971189

Advances in the use of exosomes for the treatment of ALI/ARDS

Front Immunol. 2022 Aug 9:13:971189. doi: 10.3389/fimmu.2022.971189. eCollection 2022.

Authors

Chang Liu^{1

2

3}, Kun Xiao^{2

3}, Lixin Xie^{1

2

3}

Affiliations

¹ School of Medicine, Nankai University, Tianjin, China.
² Center of Pulmonary & Critical Care Medicine, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
³ Medical School of Chinese People's Liberation Army (PLA), Beijing, China.

Abstract

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a critical clinical syndrome with high morbidity and mortality. Currently, the primary treatment for ALI/ARDS is mainly symptomatic therapy such as mechanical ventilation and fluid management. Due to the lack of effective treatment strategies, most ALI/ARDS patients face a poor prognosis. The discovery of exosomes has created a promising prospect for the treatment of ALI/ARDS. Exosomes can exert anti-inflammatory effects, inhibit apoptosis, and promote cell regeneration. The microRNA contained in exosomes can participate in intercellular communication and play an immunomodulatory role in ALI/ARDS disease models. This review discusses the possible mechanisms of exosomes in ALI/ARDS to facilitate the development of innovative treatments for ALI/ARDS.

Keywords: acute lung injury; acute respiratory distress syndrome; exosomes; inflammation; treatment.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Acute Lung Injury* / therapy
Exosomes*
Humans
Morbidity
Respiration, Artificial
Respiratory Distress Syndrome* / therapy